Biotech News

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics (PRLD)Prelude TherapeuticsEarnings

Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated in the 2 nd half of 2027 Entered into a clinical trial collaboration and supply agreement with Lilly to evaluate PRT13722 in

Related news

Prelude Therapeutics

Precision Oncology Company Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition. PRT12396 PRT12396 selectively inhibits mutant JAK2V617F and is in Phase 1 development for polycythemia vera and myelofibrosis. PRT13722 PRT13722 is an oral KAT6A degrader intended for...

Recent company news

Stock data

Close
3.26 USD
Market cap
278.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States